Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Alogliptin/Pioglitazone FDC vs Individual Tablets in Healthy Russian Subjects
NCT03501277Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pioglitazone in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours. Started May 2018; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03501277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03501277.